Week in Review: FDA reviews patient injuries | America’s heart failure epidemic | A new recall | A call to action | TAVR trends

To address this latest safety concern, the third in three months, the company is updating each device and then returning it to the customer.

Mount Sinai Fuster Heart Hospital aims to take its use of AI during interventional procedures to the next level and find new ways to transform patient care. 

Approximately one in four Americans will develop heart failure in their lifetime, according to a new report from the Heart Failure Society of America. What can be done to combat this worrisome trend?

Cardiovascular disease remains the world’s leading cause of death, according to a special report from the American College of Cardiology. The new analysis, described by one cardiologist as a "wake-up call," includes data from more than 200 countries and territories.

Some controllers were assembled with an incorrect part, potentially impacting device performance. The FDA shared an early alert about this issue in August. It has been linked to one patient's death. 

TAVR reintervention rates remain low. However, they are slowly rising as the procedure is used more to treat patients with severe aortic stenosis. Researchers think this trend may continue going forward.

An updated version of Heartflow's Plaque Analysis platform has gained FDA clearance. In addition, the company announced that Cigna will cover the platform going forward.

Several groups collaborated on the document, which is designed to help clinicians provide high-quality, consistent care when using flurpiridaz during cardiac PET imaging exams. 

Pediatric cardiologists can make a significant impact on global health trends by looking for early warning signs of CVD in their patients and collaborating with other physicians.

Screening TAVR patients for CAS may provide significant value, according to a new meta-analysis of 15 different studies.